Ruiz GD, Olivera LI, Gómez VN

Idioma: Español
Referencias bibliográficas: 16
Paginas: 72-77
Archivo PDF: 147.13 Kb.

RESUMEN

La mioclonía poshipoxia crónica o síndrome de Lance Adams es una complicación rara que se produce en pacientes que sobreviven a la hipoxia o la hipotensión prolongada, días o semanas después del daño cerebral. Se presentó un caso con este síndrome, secundario a shock hipovolémico por embarazo ectópico roto. El electroencefalograma con ausencia de paroxismos apoya el origen subcortical de las mioclonías, con respuesta favorable al alonazepán. Se detallaron estudios de neuroimagen y potenciales evocados auditivos de tallo cerebral.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Caviness JN, Brown P. Myoclonus: current concepts and recent advances. Lancet Neurol. 2004;3:598-607.

2. Lance JW, Adams RD. The syndrome of intention or action myoclonus as a sequel to hypoxic encephalopathy. Brain. 1963;86(1):111-36.

3. Welsh JP, Placantonakis DG, Warsetsky SI, Marquez RG, Bernstein L, Aicher SA. The serotonin hypothesis of myoclonus from the perspective of neuronal rhythmicity. Adv Neurol. 2002;89(1):307-29.

4. Richardson JC, De Léan J, Hornykiewicz O. Beneficial effects of serotonin precursors in postanoxic action myoclonus.Neurology. 1976;26(9):863-8.

5. Lhermitte F, Talairach J, Buser P. Myoclonies d'intention et d'action postanoxiques: Etude stereotaxique et destruction du noyau central lateral du thalamus. Rev Neurol. 1971;124:1-20.

6. Welsh JP, Yuen G, Placantonakis DG, Vu TQ, Haiss F, O'Hearn E, et al. Why do Purkinje cells die so easily after global brain ischemia? Aldolase C, EAAT4, and the cerebellar contribution to posthypoxic myoclonus. Adv Neurol. 2002;89(2):331-59.

7. Yan-xing Zhang, Jian-ren Liu, Biao Jiang, Hui-qin Liu, Mei-ping Ding,Shui-jiang Song, et al. Lance-Adams syndrome: a report of two cases. Journal of Zhejiang University Science. 2007;8(10):11-13.

8. Dubinsky RM, Hallett M, Di Chiro G, Fulham M, Schwankhaus J. Increased glucose metabolism in the medulla of patients with palatal myoclonus. Neurology. 1991;41(4):557-62.

9. Frucht SJ, Trost M, Ma Y, Eidelberg D. The metabolic topography of posthypoxic myoclonus. Neurology. 2004;62(10):1879-81.

10. Frucht SJ, Fahn S. The clinical spectrum of posthypoxic myoclonus. Mov Disord. 2000;15 (Suppl 1):2-7.

11. Frucht SJ, Louis ED, Chuang C, Fahn S. A pilot tolerability and efficacy study of Levetiracetam in patients with chronic myoclonus. Neurology. 2001;57(6):111-24.

12. Krauss GL, Bergin A, Kramer RE, Cho YW, Reich SG. Suppression of post-hypoxic and post-encephalitic myoclonus with Levetiracetam. Neurology. 2001;56(3):411-2.

13. Lim LL, Ahmed A. Limited efficacy of Levetiracetam on myoclonus of different etiologies. Parkinsonism Relat Disord. 2005;11(2):135-7.

14. Guo XH, Yu SY, Liu J, Wu WP, Pu CQ, Zhu K. Posthypoxic myoclonus treated with 5-hydroxytryptophan: a case report. J Clin Neurol. 2002;15(5):313.

15. Arpesella R, Dallocchio C, Arbasino C, Imberti R, Martinotti R, Frucht SJ. A patient with intractable posthypoxic myoclonus (Lance-Adams syndrome) treated with sodium oxybate. Anaesth Intens Care. 2009;1(1):1-2.

16. Werhahn KJ, Brown P, Thompson PD, Marsden CD. The clinical features and prognosis of chronic posthypoxic myoclonus. Mov Disord. 1997;12(2):216-20.